Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited
• Treatments: Atorvastatin; Atorvastatin Calcium; Irbesartan

Criteria

Inclusion Criteria:

• Aged between 19 and 75 years

• Signed informed consent

Exclusion Criteria:

• At screening, SPB ≥ 180mmHg or DBP ≥ 110mmHg or LDL-C > 250mg/dL or TG ≥ 400mg/dL

• Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMG-CoA reductase inhibitor or component of this drug

• Has a history of multi-drug allergy